Abstract. We elucidated the pharmacological properties of a novel nonpeptide vasopressin V 2 -receptor agonist, OPC-51803 ((5R)-2-[1-(2-chloro-4-(1-pyrrolidinyl)benzoyl-2,3,4,5-tetrahydro-1H-1-benzazepine-5-yl]-N-isopropylacetamide), via both in vitro binding experiments incorporating canine kidney and platelet membrane fractions and in vivo experiments that would determine the compound's antidiuretic effects after oral administration to water-loaded dogs.
Introduction
Arginine vasopressin (AVP) is a peptide hormone that increases water permeability through the V 2 receptor at renal collecting ducts. Antidiuretic action is caused from a rise in cyclic adenosine 3',5'-monophosphate (cAMP) production and water channel transfer (aquaporin-2) from stores in intracellular vesicles to the apical plasma membrane. Hence, AVP plays an important role in maintaining water homeostasis.
Recently, we discovered a nonpeptide AVP V 2 -receptor agonist, OPC-51803 (1, 2) , by the lead optimization of congeners found in the nonpeptide V 2 -receptor antagonists OPC-31260 (3, 4) and OPC-41061 (5 -7). In in vitro binding experiments, OPC-51803 selectively bound to V 2 receptors in human AVP receptor subtypeexpressing HeLa cells and rat plasma membranes. In addition, in vivo experiments showed that orally administered OPC-51803 significantly decreased urine volume and increased urinary osmolality in both Brattleboro rats (have a hereditary AVP deficiency) and normally hydrated rats. Although the results show that OPC-51803 is a potent antidiuretic in rats, the compound's effects in dogs have not been elucidated.
In previous reports, AVP analogs, which are either peptide or nonpeptide compounds, showed a difference between animal species (8 -11) . In particular, peptide V 2 -receptor antagonists (e.g., SK&F 101926) showed potent diuresis by inhibiting the action of endogenous AVP in rats. In water-loaded dogs, however, it had the opposite effect (8, 9) . Here, we estimated OPC-51803's affinity for canine V 2 receptors and its agonistic activities in water-loaded dogs and also determined the pharmacological profile of OPC-51803 (including renal hemodynamics).
Materials and Methods

Materials
OPC 
Animals
Male beagle dogs (9.3 -10.9 kg) and mongrel dogs (12 -22 kg) were purchased from Nihon Nosan Kogyo (Yokohama) and Kitayama Labes Co., Ltd. (Nagano), respectively. The dogs were housed in a temperature-, humidity-, and light-controlled room and given 300 to 400 g per day of food (CD-5; Clea Japan, Inc., Tokyo) along with free access to water. The care and handling of these animals were in accordance with "Guidelines for Animal Care and Use in Otsuka Pharmaceutical Co., Ltd.," October 1, 1994.
Membrane preparations of canine platelet and kidney medulla
Crude platelet membrane fractions were prepared immediately before each binding experiment at 1-week intervals by modifying previously described methods (12, 13) . Briefly, blood was obtained from the cephalic vein of six conscious beagle dogs. The blood was anticoagulated with 3.8% sodium citrate (1:9 v:v) and centrifuged at 200´g for 15 min at room temperature. The supernatant (platelet-rich plasma) was centrifuged at 2,000´g for 15 min at room temperature. The obtained pellets were washed twice and resuspended in a cooled 50 mM Tris-HCl buffer (pH 7.4) containing 10 mM MgCl 2 and 2 mM EDTA using a Microson TM (Heat Systems Ultrasonic Inc., Farmingdale, NY, USA) and then recentrifuged (30000´g for 30 min at 4°C). The pellets were resuspended in 50 mM Tris-HCl buffer.
Canine kidney membranes were prepared as follows: Two beagle dogs were exsanguinated from the cervical arteries under anesthesia with sodium pentobarbital.
All kidneys were isolated, and the cortex and adipose tissues were removed to leave as much of the medulla as possible. The medulla was minced with scissors and homogenated using a Polytron ® (setting 6, 15 s, 2 times; Kinematica AG, Lucerne, Switzerland) in a 0.25 M sucrose buffer (pH 7.4) containing 5 mM MgCl 2 , 1 mM EDTA, and 10 mM Tris. The suspension was centrifuged at 2000´g for 15 min at 4°C, then the pellets were resuspended by the PEG-DEX double-phase system to obtain a membrane fraction at an interfacial phase. The membrane fraction was washed twice with phosphate-buffered saline (PBS), suspended in 50% glycerol-PBS, and stored at -80°C until use. A sample of each preparation was dissolved in 0.1 N NaOH, and the resulting protein was quantitated by the dye method (14) using BSA as a standard.
Radioligand binding assay of canine platelet and kidney membrane fractions
For the saturation binding studies, each membrane preparation was incubated with [ 3 H]AVP and kidney membranes. Samples were incubated for 10 min at 37°C (platelet membranes) or 20 min at 25°C (kidney membranes). In preliminary studies we confirmed that the preparations achieved equilibrium under these conditions (data not shown).
Radioligand binding data analysis
The dissociation constant (K D ) and the number of binding sites (B max ) were determined by Scatchard analysis (15) . The IC 50 values of OPC-51803, AVP, and DDAVP were determined by a displacement procedure using [
3 H]AVP binding, and the resultant curves were resolved to obtain the concentrations required for a 50% inhibition of specific binding. The inhibition constants (K i ) were calculated from the IC 50 values using the Cheng and Prusoff equation (16) .
Antidiuretic action of OPC-51803 in water-loaded dogs
To induce water diuresis, 50 ml × kg -1 of tap water was administered to beagle dogs using a stomach tube. After physically restraining the dogs with loose slings, one indwelling catheter was inserted in the cephalic vein to infuse a hypotonic solution (3% glucose solution) and once was inserted in the bladder to gather urine samples. The intravenous infusion rate of a hypotonic solution was initially about 5 ml × min -1 and equal to the rate of urine excretion after urine volume became constant. OPC-51803 (0.03, 0.1, and 0.3 mg × kg -1 ) and 5% gum arabic (vehicle) were orally administered to the dogs using a stomach tube. Urine was collected every 5 min over a 60-min period. Urinary osmolality was determined with a Fiske Osmometer (Model 3400; Fiske Associates, Norwood, MA, USA) by analyzing the freezing-point depression of an aliquot of collected urine. Each dog underwent the above procedure and received the three doses of the drug and vehicle in random order at approximately 2-week intervals.
Effects of OPC-51803 on hemodynamics in anesthetized dogs
Mongrel dogs were anesthetized with a bolus injection (30 mg × kg -1 , i.v.) and a subsequent infusion
) of sodium pentobarbital, intubated, and artificially ventilated with room air using a respirator (Model SN-480-3; Shinano, Tokyo). The cephalic vein was cannulated for drug administration. The brachial artery was cannulated to collect arterial blood samples; mean arterial pressure (MAP) and heart rate (HR) were measured with a pressure transducer. A catheter was inserted into the left ureter to collect urine. The left kidney was exposed by a retroperitoneal flank incision, and an electromagnetic flow probe (2.5 -3.5 mm in diameter; Nihon Kohden, Tokyo) was attached to the renal artery to measure renal blood flow (RBF) with a square-wave flowmeter (MFV-2100, Nihon Kohden). Inulin, dissolved in a hypotonic solution (0.45% NaCl and 2.5% dextrose), was given intravenously at an initial dose of 50 mg × kg -1 and infused at a dose of
) to measure inulin clearance, which is an index of glomerular filtration rate (GFR). After surgery, the animals were allowed to rest for 60 to 180 min to allow urine volume and hemodynamic parameters to stabilize.
When urine was constantly excreted, samples were collected over 20-min periods to measure two consecutive basal values. Then, OPC-51803 (0.3 and 3.0 m g
) or 20% dimethylformamide (vehicle) was intravenously infused at a rate of 0.2 ml × min -1 over a 60-min period, and urine was collected for three consecutive 20-min periods. At the midpoint of each period, arterial blood samples were drawn and MAP, HR, and RBF were recorded on a polygraph system (Recti-horiz-8K; NEC-San-ei, Tokyo). GFR was calculated as follows: GFR = urine flow rate (ml × min -1 )´U inulin / P inulin , where U inulin is urinary inulin concentration, and P inulin is plasma inulin concentration. The inulin concentrations were measured by Anthrone methods (Spectrophotometer, Spectra Max 250; Wako) (17) . Urinary and plasma osmolality were determined using the Fiske Osmometer; and sodium, potassium, and urea nitrogen concentrations were measured by ion-selective potentiometry and an enzymatic-conductivity rate method using an autoanalyzer (Synchron CX-3; Beckman Instruments, Brea, CA, USA). Plasma AVP concentrations were measured by radioimmunoassay (Mitsubishi Chemical, Tokyo).
Analysis of in vivo data
All values were expressed as means ± S.E.M. Urine flow, GFR, RBF, and urinary excretions of sodium, potassium, and urea nitrogen were divided by the body weight of each dog. The differences between the vehicle-treated and OPC-51803-treated groups for urine, plasma, and hemodynamic parameters were determined by repeated measures ANOVA. When either the effects of a group or group-time interaction were significant, the difference at each time point was analyzed by a two-tailed Dunnett's multiple comparison test. The differences were considered significant at P<0.05. 
Results
Antidiuretic action of single, oral OPC-51803 dose in water-loaded male dogs
In conscious beagle dogs, a bolus oral administration of water followed by an intravenous infusion of a hypotonic solution led to continuous increases in urine excretion: Excreted urine volume increased to about 20 ml × 5 min -1 , and urinary osmolality decreased to less than 100 mOsm × kg -1 . In the vehicle-treated group, neither urine volume nor urinary osmolality changed throughout the experiment. Orally administered OPC-51803 decreased urine volume and increased urinary osmolality in a dose-dependent manner (Fig. 1) . At doses of 0.1 and 0.3 mg × kg -1 , significant decreases in urine volume were seen just after 15 min postdose.
Effects of intravenous OPC-51803 infusion on hemodynamics and renal functions in anesthetized dogs
OPC-51803 was intravenously infused at doses of 0.3 and 3 mg × kg -1 × min -1 . Compared with the vehicletreated group, a significant decrease in urine volume and an increase in urinary osmolality was seen in the group treated with 3 m g × kg -1 × min -1 (Fig. 2) . Systemic hemodynamic parameters, such as MAP and HR, remained unchanged (Fig. 3) . Statistically significant . Differences between each OPC-51803-treated group and the vehicle-treated group were statistically analyzed by repeated measures ANOVA. Any significant differences were then analyzed by a two-tailed Dunnett's multiple comparison test at each time. *P<0.05, **P<0.01. differences were not seen, either, in GFR or RBF, which is an index of renal functions, between the vehicletreated group and OPC-51803-treated groups (Fig. 3) . The effects of OPC-51803 on urinary parameters are shown in Table 2 . At 3 m g × kg
, OPC-51803 significantly decreased urinary urea nitrogen excretion at the first and second periods after drug infusion was initiated. Although there was a tendency for decreased urinary sodium excretion, it remained statistically insignificant. OPC-51803 did not affect hematocrit, plasma osmolality, or plasma concentrations of AVP, sodium, potassium, or urea nitrogen (Table 3 ).
Discussion
We demonstrated that OPC-51803, a nonpeptide, is an AVP V 2 agonist in dogs. After using platelets and kidney medulla membranes to evaluate the affinities of OPC-51803 for canine V 1a and V 2 receptors (18, 19) , the drug showed an affinity for both receptors. The K i value of OPC-51803 for V 2 receptors was of the same order as those for rat (49.8 ± 8.1 nM) and human (91.9 ± 10.8 nM) V 2 receptors (1, 2). OPC-51803 showed an affinity for canine V 1a receptors but the affinity was lower than that for V 2 receptors. A peptide AVP V 2 agonist, DDAVP, also showed a higher affinity for V 2 receptors. These data show that, as with DDAVP, OPC-51803 has a selective affinity for V 2 receptors in dogs.
As for antidiuretic effects, orally administered OPC-51803 dose-dependently decreased urine volume and increased urinary osmolality in water-loaded dogs. Identical results reported show that AVP and its analogs have V 2 agonistic activities (20) . From these results, we confirm OPC-51803's antidiuretic action in dogs (as with rats) via V 2 -receptor stimulation.
Next, we evaluated the influences of OPC-51803 on systemic hemodynamics and renal functions in anesthetized dogs. OPC-51803 was intravenously infused to maintain constant plasma OPC-51803 concentrations. At 3 mg × kg -1 × min -1 , which induced significant antidiuresis, OPC-51803 scarcely exerted a response on MAP or HR. Aki et al. (21) reported that after preadministering a V 1 -receptor antagonist, an intrarenal infusion of AVP caused RBF to increase without pressor action in pentobarbital-anesthetized euvolemic dogs. Naitoh et al. (22) also showed that an intravenous infusion of DDAVP significantly increased RBF in conscious dogs via V 2 -receptor activation. In the present study, OPC-51803 tended to increase RBF in the first period of drug infusion, but the changes were not statistically significant. In order to clarify renal vasodilation via V 2 -receptor stimulation induced by OPC-51803, more detailed estimation may be needed. OPC-51803 significantly decreased urinary excretion of urea. AVP reportedly activates urea transporters via V 2 -receptors and promotes urea reabsorption in the inner medullary collecting duct in rats (23, 24) . In the same way, OPC-51803 may induce urea reabsorption through the activation of urea transporters via V 2 -receptors, thereby decreasing urinary urea nitrogen excretions in dogs.
In conclusion, OPC-51803 has an affinity for V 2 receptors and shows antidiuresis after oral administration, but has little influence on systemic hemodynamics or renal functions in dogs. At present, synthetic AVP and DDAVP are used in patients with central diabetes insipidus and some kinds of nocturnal enuresis, nocturia, Values are expressed as the mean (±S.E.M.) of seven experiments. Statistical analyses were performed by repeated measures ANOVA. Any significant differences were then analyzed by a two-tailed Dunnett's multiple comparison test at each time, but no significant differences were seen in any parameters between the vehicle-treated group and OPC-51803-treated groups.
and polyuria (25 -30) . It has also been reported that orally administered DDAVP decreased urine volume in Brattleboro rats (AVP-deficient), water-loaded dogs, and even patients with central diabetes insipidus, although DDAVP is a peptide compound (20) . However, oral DDAVP presents problems such as large interand intraindividual variation (31, 32) attributed to low bioavailability (e.g., less than 1% in humans) (33, 34) . Finally, OPC-51803 is absorbed well and shows oral effectiveness in vivo. Therefore, OPC-51803 may provide a new treatment for patients with pathophysiological AVP deficiency.
